Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia Enrolling
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Last Patient Last Visit Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

For more details, click here for the full news release.

Continue

Ocuphire in the News

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

The Wall Street Analyzer

Mar 26, 2021

OIS Weekly: Company/Market Watch – Ocuphire Pharma Reports Positive Top-line Results in the MIRA-2 Phase III Registration Trial

Mar 24, 2021

Ocuphire Represented by Mina Sooch Participated in Crain’s Detroit's Event: “M&A Lessons from the Biggest Deals of 2020"

Mar 10, 2021

Encode Ideas, L.P. Announces the Initiation of Research Coverage on Ocuphire Pharma Inc.

Nov 9, 2020

Biotech entrepreneur Sooch completes merger to take latest company public

Nov 6, 2020

Mediaplanet’s 2020 Vision Health Edition Features Night Vision Disturbances and Ocuphire Pharma’s Leadership in Investigating Potential Treatments for the Condition

Sep 30, 2020

Sooch raises $5 million for new venture, ophthalmology Pharma company Ocuphire

Jul 21, 2020

Farmington Hills biotech company Ocuphire strikes deal that will put it on stock exchange

Jun 24, 2020
RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
Ocuphire Pharma, Inc.
© Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use